![]() |
|
|
Vol. 297, Issue 2, 620-628, May 2001
Fujisawa Institute of Neuroscience, Department of Neuroscience,
University of Edinburgh, Edinburgh, United Kingdom
The action of FK960
[N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide
monohydrate], a novel cognitive enhancer, on excitatory synaptic
transmission in the hippocampus was investigated. Excitatory postsynaptic potentials (EPSPs) and currents (EPSCs) were
recorded intracellularly from CA1 neurons in rat hippocampus using the "blind patch" variant of whole-cell recording. FK960 (100 nM) significantly increased the amplitude of the EPSP, which was unchanged when changeover was made to control artificial cerebrospinal fluid (aCSF). FK960 had no significant action on membrane potential, input
resistance, or the early GABAergic inhibitory postsynaptic current. The
decay phase of the excitatory postsynaptic current was not
significantly altered by exposure to FK960, indicating that the
properties of desensitization and/or deactivation were unchanged and
suggesting that the action of FK960 was unlikely to be the result of
changes in the properties of the postsynaptic (S)-
-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic
acid (AMPA) receptors. The quantal content of the EPSP
(1/CV2) increased after exposure to FK960 but not to
control aCSF. Methyllycaconitine or
-bungarotoxin blocked the
modulatory action of FK960 on the EPSP, and the finding that these
7-nicotinic acetylcholine receptor (
7nAChR) antagonists were
effective raises the possibility that FK960 up-regulates the
contribution of acetylcholine to synaptic efficacy in the hippocampus.
It is concluded that FK960 increases the quantal release of glutamate
from Schaffer collateral-commissural nerve terminals in area CA1 of the
hippocampus either by changing the ambient level of acetylcholine or by
positively modulating the activity of
7nAChRs located on
glutamatergic nerve terminals.